This population-based study examines the incidence and risks for development of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) in patients who have received chemotherapy for primary solid cancers.
This national survey study of patients with cancer evaluates the association between patient comorbid conditions and cancer clinical trial participation.
This phase 1b multicohort study assessed 33 patients with advanced triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel to examine its safety, tolerability, and preliminary clinical activity.
This multicenter, phase 2, single-arm trial assesses the activity of cetuximab plus irinotecan as third-line treatment for patients with RAS and BRAF wild-type metastatic colorectal cancer who were initially sensitive to and then resistant to first-line irinotecan- and cetuximab-based therapy.
This phase 1b clinical trial assesses the safety and efficacy of avelumab treatment in a multinational cohort of patients with unresectable, previously treated malignant mesothelioma.
This study explores the cost-effectiveness and potential budgetary consequences of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer (NSCLC) in the context of the US health care system.
This study examines HER2 ISH-equivocal breast cancers to asses 2013/2014 American Society of Clinical Oncology and College of American Pathologists guidelines in determining HER2-positive or HER2-negative breast cancers and false-positive results.
This medical records analysis from a single institution in Japan assesses anti–PD-1 treatment in patients with subclinical advanced non–small cell lung cancer and with or without preexisting autoimmune markers and evaluates potential clinical biomarkers that may be associated with clinical benefit or with immune-related adverse events.
This cross-sectional study analyzes the proportion of cancer cases attributable to excess body weight in each US state using data from several databases.
This phase 1b open-label study assesses the efficacy and safety of avelumab, an anti–programmed death ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer.
This secondary analysis of a randomized clinical trial examines the association of modern chemoradiotherapy with survival among patients with stage I to II small cell lung cancer compared with that among patients with stage III small cell lung cancer.
This study searched ClinicalTrials.gov to examine the reporting rates of research biopsies conducted in oncology clinical trials amd investigates what factors correlate with research biopsy reporting.
This case study documents osteosarcoma in 240-million-year-old stem-turtle, which suggests that cancer is not a modern physiological defect.
This cross-sectional study of data from the National Health Interview Survey analyzes the prevalence of e-cigarette use in US patients with cancer.
This Special Contribution discusses newly revised regulations for human research affecting the use biospecimens and makes recommendations to enable ethically appropriate regulation of biospecimen research across the spectrum of cancer research.
This narrative review discusses the rationale and results of clinical trials in immunotherapy-based combination therapy for patients with advanced renal cell carcinoma.
This case report describes an unusual case of hyperhidrosis associated with apical lung cancer with sympathetic nerve involvement.
This Viewpoint discusses obstacles that limit the use of biosimilar filgrastim in the United States compared with countries in the European Union and Japan and discusses strategies that might help biosimilar filgrastim use become more widespread.
This Viewpoint describes the benefits of the Oncology Care Model, Medicare’s first cancer-specific alternative payment model, compared with other value-based payment models.
This Viewpoint argues against policies mandating the patient consent process for publication and institutional review board approval of case studies.
This Patient Page defines stereotactic body radiation therapy and describes how and in what situations it is administered to treat certain patients with cancer.
This article describes the coping mechanism used by a patient with cancer.
Create a personal account or sign in to: